Affinage

TSC22D4

TSC22 domain family protein 4 · UniProt Q9Y3Q8

Length
395 aa
Mass
41.0 kDa
Annotated
2026-04-28
12 papers in source corpus 13 papers cited in narrative 13 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

TSC22D4 is a leucine zipper transcription factor and protein adaptor that integrates metabolic, inflammatory, and oncogenic signaling across multiple cell types. In hepatocytes, TSC22D4 transcriptionally represses lipogenic and VLDL secretion genes and the hepatokine LCN13 to control systemic lipid and glucose homeostasis, and directly binds Akt1 via its intrinsically disordered D2 domain under energy deprivation to dampen basal Akt phosphorylation and promote insulin sensitivity (PMID:23307490, PMID:27827363, PMID:36269831). Hepatocyte-specific deletion derepresses mitochondrial metabolism and ameliorates NASH-associated steatosis and inflammation (PMID:35378329). In squamous cell carcinoma, TSC22D4 competitively inhibits NRBP1's E3 ubiquitin ligase activity to stabilize SALL4 and TRAF6, thereby sustaining stemness gene expression and NF-κB–driven inflammatory signaling, and is phosphorylated by the RTK-RAS-ERK pathway to promote tumorigenesis and regulate CD44 alternative splicing (PMID:31864704, PMID:39869046, PMID:37607779).

Mechanistic history

Synthesis pass · year-by-year structured walk · 10 steps
  1. 2012 Medium

    TSC22D4 was shown to be functionally required for neuronal differentiation, establishing it as more than a passive transcription factor and revealing context-dependent subcellular redistribution during development.

    Evidence siRNA knockdown in CGNs and N1E-115 neuroblastoma cells with neurite elongation readout plus localization imaging during differentiation

    PMID:20878296

    Open questions at the time
    • Single lab observation
    • Neuronal target genes unidentified
    • Mechanism linking TSC22D4 redistribution to differentiation unknown
  2. 2013 Medium

    Discovery that TSC22D4 exists as multiple differentially modified isoforms (42–72 kDa) with distinct subcellular localizations and binding partners revealed unexpected complexity, including mitochondrial entry and O-GlcNAcylation, suggesting post-translational regulation of its function.

    Evidence Biochemical fractionation, co-immunoprecipitation, and mass spectrometry of PTMs in CGNs

    PMID:23305244

    Open questions at the time
    • Functional significance of each isoform not established
    • Mitochondrial role not independently validated
    • O-GlcNAcylation functional consequence unknown
  3. 2013 High

    Bidirectional hepatic manipulation established TSC22D4 as a transcriptional repressor of lipogenic and VLDL secretion programs, resolving how the liver controls systemic triglyceride availability and linking hepatic TSC22D4 to cancer cachexia-associated hypolipidemia.

    Evidence Liver-specific overexpression and ablation in mice with VLDL secretion and lipogenic gene quantification

    PMID:23307490

    Open questions at the time
    • Direct transcriptional targets mediating VLDL repression not fully identified
    • Mechanism of TSC22D4 upregulation in cachexia unknown
  4. 2016 High

    Identification of LCN13 as a direct transcriptional target of hepatic TSC22D4 explained how a liver transcription factor controls systemic glucose homeostasis and insulin sensitivity, providing a therapeutic rationale for TSC22D4 inhibition in diabetes.

    Evidence Hepatic loss-of-function in diabetic mouse models, direct transcriptional regulation of LCN13, correlation with human diabetic data

    PMID:27827363

    Open questions at the time
    • How LCN13 signals to peripheral tissues to improve glucose homeostasis unresolved
    • Whether TSC22D4 binds the LCN13 promoter directly or via co-factors not fully dissected
  5. 2019 Medium

    Two studies expanded TSC22D4's role beyond metabolism: knockout induced senescence via JUNB–P21, and TSC22D4 was found to stabilize SALL4 by competitively inhibiting NRBP1-mediated ubiquitination, revealing a non-transcriptional adaptor function that promotes cancer stemness.

    Evidence CRISPR KO with JUNB epistasis (siRNA rescue of P21); Co-IP of TSC22D4–NRBP1, ubiquitination assays, SALL4 rescue in ESCC cells

    PMID:31806366 PMID:31864704

    Open questions at the time
    • How TSC22D4 suppresses JUNB transcription unknown
    • Whether NRBP1 inhibition is direct competition or allosteric not resolved
    • Single-lab findings for both observations
  6. 2022 High

    Direct binding of TSC22D4 to Akt1 through its disordered D2 domain under starvation conditions provided a mechanistic explanation for how TSC22D4 tunes insulin signaling: the interaction reduces basal Akt phosphorylation, and its release upon refeeding permits full insulin responsiveness.

    Evidence Co-immunoprecipitation, D2 domain mapping, liver-specific reconstitution in mice with glucose tolerance testing

    PMID:36269831

    Open questions at the time
    • Structural basis of D2–Akt1 interaction unresolved
    • Whether TSC22D4–Akt interaction occurs in non-hepatic tissues unknown
  7. 2022 High

    Hepatocyte-specific TSC22D4 deletion upregulated mitochondrial TCA cycle and triglyceride metabolism programs and ameliorated NASH, establishing TSC22D4 as a tonic repressor of hepatic mitochondrial function and a candidate therapeutic target in fatty liver disease.

    Evidence Hepatocyte-specific KO, single-nuclei RNA-seq, multiple NASH diet models

    PMID:35378329

    Open questions at the time
    • Direct transcriptional targets mediating mitochondrial repression not identified
    • Whether the benefit is hepatocyte-autonomous or involves stellate cell cross-talk not resolved
  8. 2022 Medium

    TSC22D4 was found to promote TGFβ1-mediated hepatic stellate cell activation, broadening its liver role from a hepatocyte-intrinsic factor to an activator of fibrogenic cell types.

    Evidence Loss-of-function in HSCs, RNA-seq, migration and proliferation assays

    PMID:35714570

    Open questions at the time
    • Whether TSC22D4 acts cell-autonomously in HSCs or via paracrine signals unknown
    • Direct target genes in HSCs unidentified
  9. 2023 Medium

    Phosphorylation of TSC22D4 by the RTK-RAS-ERK pathway linked it to oncogene-driven tumorigenesis and CD44 alternative splicing, demonstrating that post-translational modification switches TSC22D4 into a pro-tumorigenic effector.

    Evidence Phospho-specific antibody, knockdown/overexpression in SCC cells, xenograft assays, CD44 splicing analysis

    PMID:37607779

    Open questions at the time
    • Specific ERK phosphorylation sites on TSC22D4 not mapped
    • Mechanism linking TSC22D4 phosphorylation to CD44 splicing unknown
    • Single-lab study
  10. 2025 Medium

    TSC22D4 was shown to stabilize TRAF6 by inhibiting NRBP1-dependent ubiquitination, sustaining NF-κB signaling and IL-1-mediated inflammation in SCC, generalizing the NRBP1-inhibition mechanism to a second substrate beyond SALL4.

    Evidence Co-IP of TSC22D4–NRBP1, TRAF6 ubiquitination assay, NF-κB nuclear translocation readout

    PMID:39869046

    Open questions at the time
    • Whether TRAF6 stabilization and SALL4 stabilization are concurrent or context-dependent unknown
    • Structural basis of NRBP1 inhibition unresolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include the structural basis of TSC22D4's interaction with Akt1 and NRBP1, the identity of direct transcriptional targets mediating mitochondrial repression, whether direct glucose binding (mapped to the leucine zipper) serves a physiological sensing role, and how the adaptor function in the WNK osmotic stress complex integrates with metabolic signaling.
  • No crystal or cryo-EM structure of TSC22D4 or its complexes
  • Glucose-binding functional consequence not established in vivo
  • WNK pathway role awaits independent confirmation and functional dissection

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060090 molecular adaptor activity 3 GO:0098772 molecular function regulator activity 3 GO:0140110 transcription regulator activity 3
Localization
GO:0005634 nucleus 2 GO:0005739 mitochondrion 1 GO:0005829 cytosol 1
Pathway
R-HSA-1430728 Metabolism 3 R-HSA-162582 Signal Transduction 3 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-168256 Immune System 1
Partners
AKT1JUNBLCN13NRBP1SALL4TRAF6TSC22D1

Evidence

Reading pass · 13 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2013 TSC22D4 functions as a hepatic transcription factor that inhibits VLDL secretion and lipogenic gene expression; elevated hepatic TSC22D4 in cancer cachexia drives reduced systemic VLDL levels, while liver-specific ablation triggers hypertriglyceridemia through induction of hepatic VLDL secretion. Liver-specific overexpression and ablation (loss-of-function) in mice with metabolic phenotyping (VLDL secretion, lipogenic gene expression) EMBO molecular medicine High 23307490
2016 Hepatic TSC22D4 directly transcriptionally regulates the small secretory protein lipocalin 13 (LCN13) to control systemic glucose homeostasis; hepatic TSC22D4 inhibition prevents and reverses hyperglycemia, glucose intolerance, and insulin resistance in diabetic mouse models. Hepatic loss-of-function in vivo, direct transcriptional regulation of LCN13 established, correlation with human diabetic patient data Nature communications High 27827363
2012 TSC22D4 subcellular localization shifts from nuclear/cytoplasmic in undifferentiated cerebellar granule neurons (CGNs) to somatodendritic/synaptic compartments upon maturation; TSC22D4 silencing with siRNAs blocks CGN differentiation and inhibits neurite elongation. In vivo and in vitro localization during CGN differentiation, siRNA knockdown with neurite elongation readout in N1E-115 neuroblastoma cells Cerebellum (London, England) Medium 20878296
2013 TSC22D4 exists as multiple iso- and phospho-glycoforms with distinct subcellular localizations and interacting partners during CGN differentiation: the 42 kDa form is cytosolic and associates with TSC22D1.2 only in undifferentiated CGNs; the 55 kDa form associates with the nuclear matrix in differentiated CGNs; the 67 kDa form enters mitochondria in differentiated CGNs and associates with apoptosis-inducing factor; the 72 kDa form is O-GlcNAcylated and phosphorylated and is constitutively chromatin-associated. Biochemical fractionation, co-immunoprecipitation, mass spectrometry identification of post-translational modifications (O-GlcNAcylation, phosphorylation) The FEBS journal Medium 23305244
2019 TSC22D4 (THG-1) knockout induces cellular senescence through activation of the JUNB pathway, which drives transcription of the CDK inhibitor P21(CDKN1A); siRNA-mediated knockdown of JUNB reduces P21 mRNA and cellular senescence in TSC22D4 KO cells, placing TSC22D4 upstream of JUNB–P21 in senescence suppression. CRISPR/Cas9 knockout, siRNA knockdown of JUNB, mRNA quantification of P21 Biochemical and biophysical research communications Medium 31806366
2019 TSC22D4 (THG-1) binds NRBP1 and competitively inhibits NRBP1-mediated ubiquitination and degradation of SALL4, thereby stabilizing SALL4 protein and inducing stemness genes (NANOG, OCT4) to promote tumorsphere formation in esophageal squamous cell carcinoma cells. Co-immunoprecipitation (TSC22D4–NRBP1 interaction), ubiquitination assay, rescue experiment with exogenous SALL4 expression Biochemical and biophysical research communications Medium 31864704
2022 TSC22D4 directly interacts with Akt1 via its intrinsically disordered D2 domain; this interaction is promoted by energy deprivation and oxidative stress and impaired by refeeding/glucose/insulin. The TSC22D4–Akt1 interaction reduces basal Akt phosphorylation and downstream signaling during starvation, promoting insulin sensitivity. Liver-specific reconstitution experiments confirm the interaction improves glucose handling in vivo. Co-immunoprecipitation, domain mapping (D2 domain), liver-specific genetic reconstitution in mice, phosphorylation assays Science advances High 36269831
2022 Hepatocyte-specific deletion of TSC22D4 upregulates mitochondrial-related processes (TCA cycle, mitochondrial organization, triglyceride metabolism), reduces liver lipid accumulation, improves steatosis/inflammation, and decreases apoptosis in NASH mouse models, establishing TSC22D4 as a repressor of hepatocyte mitochondrial function. Hepatocyte-specific knockout (TSC22D4-HepaKO), single-nuclei RNA sequencing, NASH diet models Molecular metabolism High 35378329
2022 TSC22D4 promotes TGFβ1-mediated activation, proliferation, and migration of hepatic stellate cells (HSCs), initiating transcriptional programs associated with HSC activation as revealed by RNA-seq. Loss-of-function in HSCs, RNA sequencing, migration and proliferation assays Biochemical and biophysical research communications Medium 35714570
2023 TSC22D4 (THG-1) is phosphorylated by the RTK-RAS-ERK pathway, promoting oncogene-mediated tumorigenesis and SCC proliferation/invasiveness; TSC22D4 also regulates alternative splicing of CD44 variants downstream of RTK signaling. Phosphorylation assay with specific antibody, knockdown/overexpression in SCC cells, xenograft formation, CD44 splicing analysis Cancer science Medium 37607779
2025 TSC22D4 (THG-1) binds NRBP1 and suppresses NRBP1's E3 ubiquitin ligase activity toward TRAF6, preventing TRAF6 degradation; this stabilizes TRAF6 and sustains NF-κB nuclear translocation and IL-1-mediated inflammatory signaling in squamous cell carcinoma cells. Co-immunoprecipitation (THG-1–NRBP1), ubiquitination assay (TRAF6), siRNA knockdown, NF-κB nuclear translocation assay Molecular cancer research : MCR Medium 39869046
2025 TSC22D4 directly binds glucose; UV-crosslinking mass spectrometry maps glucose binding to the C-terminal leucine zipper region, and the I322W mutation abolishes glucose binding. Glucose binding increases accessibility of the leucine zipper and promotes intra-protein contacts between the C-terminal zipper and N-terminal intrinsically disordered domain; under high glucose, TSC22D4 associates with fatty acid metabolism machinery proteins. Thermal proteome profiling (PISA), microscale thermophoresis (MST) confirming direct glucose-protein interaction, UV-crosslinking mass spectrometry, site-directed mutagenesis (I322W), chemo-proteomics bioRxivpreprint Medium bio_10.1101_2025.05.06.651509
2024 TSC22D4 acts as an adaptor protein in the WNK osmotic stress pathway; osmotic stress promotes association of TSC22D4 with WNK1 and NRBP1 pseudokinase, and AlphaFold-3 modeling predicts two TSC22D4 RΦ-motifs interact with the CCTL1 domain of WNK1 and the CCT domain of NRBP1 to form a multi-subunit complex required for WNK pathway activation. Proximity ligation, immunoprecipitation, mass spectrometry, AlphaFold-3 structural modeling bioRxivpreprint Low bio_10.1101_2024.12.12.628181

Source papers

Stage 0 corpus · 12 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2013 TSC22D4 is a molecular output of hepatic wasting metabolism. EMBO molecular medicine 53 23307490
2016 Control of diabetic hyperglycaemia and insulin resistance through TSC22D4. Nature communications 30 27827363
2012 Subcellular TSC22D4 localization in cerebellum granule neurons of the mouse depends on development and differentiation. Cerebellum (London, England) 23 20878296
2022 TSC22D4 interacts with Akt1 to regulate glucose metabolism. Science advances 17 36269831
2019 Promotion of cellular senescence by THG-1/TSC22D4 knockout through activation of JUNB. Biochemical and biophysical research communications 13 31806366
2019 THG-1 suppresses SALL4 degradation to induce stemness genes and tumorsphere formation through antagonizing NRBP1 in squamous cell carcinoma cells. Biochemical and biophysical research communications 11 31864704
2013 Multiple TSC22D4 iso-/phospho-glycoforms display idiosyncratic subcellular localizations and interacting protein partners. The FEBS journal 10 23305244
2022 Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function. Molecular metabolism 7 35378329
2022 TSC22D4 promotes TGFβ1-induced activation of hepatic stellate cells. Biochemical and biophysical research communications 7 35714570
2023 Promotion of squamous cell carcinoma tumorigenesis by oncogene-mediated THG-1/TSC22D4 phosphorylation. Cancer science 5 37607779
2025 THG-1/TSC22D4 Promotes IL-1 Signaling through Stabilization of TRAF6 in Squamous Cell Carcinoma. Molecular cancer research : MCR 1 39869046
2025 Nanomolecular silencing of TSC22D4 mRNA via a DNAsome-siRNA for enhancing insulin sensitization in hepatocytes. Iranian journal of basic medical sciences 0 39906612